Long-term survival

Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment

M. X. Zhang, Tan, W., Zhang, R. X., Tian, Y. L., Gao, H. M., Gao, Z., Zhang, N., Zhao, J. Q., Jia, Y. F., and Wang, Y. S., Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment, vol. 13. pp. 8657-8660, 2014.

The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. The first patient was alive at 8 years with alternative conventional chemotherapy and gefitinib, and the second patient was alive at long-term follow-up with conventional chemotherapy and gefitinib or erlotinib.

Subscribe to Long-term survival